InnovAge Appoints Dr. Paul Taheri as Chief Medical Officer
InnovAge (Nasdaq: INNV) appointed Paul Taheri, MD, MBA as Chief Medical Officer, effective November 3, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
InnovAge (Nasdaq: INNV) appointed Paul Taheri, MD, MBA as Chief Medical Officer, effective November 3, 2025. Dr. Taheri is a board-certified trauma surgeon with more than 30 years of healthcare leadership, including roles as CEO and Deputy Dean for Clinical Affairs at Yale School of Medicine and CEO of the University of Vermont Medical Group. He has served as a Clinical Quality Advisor since 2019 and holds an MBA from the University of Michigan.
InnovAge serves approximately 7,740 participants across 20 centers in six states as of June 30, 2025; the appointment is framed as strengthening clinical leadership for the company’s PACE model.
Positive
- Appointment effective November 3, 2025
- 30+ years of clinical and executive healthcare experience
- InnovAge served ~7,740 participants as of June 30, 2025
Negative
- None.
Details
News Market Reaction – INNV
On Nov 4, the first trading day after this news, INNV closed 2.11% above the previous close.
Data tracked by StockTitan Argus for the Nov 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), appoints Paul Taheri, MD, MBA as its Chief Medical Officer, effective November 3, 2025.
Dr. Paul Taheri, a board-certified trauma surgeon, brings more than 30 years of healthcare leadership to InnovAge. He has served as a Clinical Quality Advisor to Welsh, Carson, Anderson & Stowe, a role he has held since 2019. Dr. Taheri previously served as CEO and Deputy Dean for Clinical Affairs at the Yale School of Medicine. His earlier leadership roles include President and CEO of the University of Vermont Medical Group, Senior Associate Dean for Clinical Affairs, and professor of surgery. He also held key positions at the University of Michigan in Ann Arbor, where he earned his MBA from the Ross School of Business. Dr. Taheri received his medical degree from New York University and completed his surgical residency at Tulane University.
“Paul brings a rare combination of clinical excellence, operational discipline, and strategic leadership to InnovAge,” said Patrick Blair, CEO. “With more than 3 decades of healthcare experience and his knowledge as a provider, we welcome him to InnovAge and are excited about the experience and stead leadership we expect him to bring to our clinical teams and the participants we serve every day.”
About InnovAge
InnovAge is a market leader in managing the care of high-cost, dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers, and government payors — “win.” As of June 30, 2025, InnovAge served approximately 7,740 participants across 20 centers in six states. https://www.innovage.com/.
Investor Contact:
Ryan Kubota
RKubota@InnovAge.com
Media Contact:
Lara Hazenfield
Lhazenfied@InnovAge.com
This press release was published by a CLEAR® Verified individual.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.